Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms.
about
Evaluation of extended and continuous use oral contraceptivesHormonal contraceptives: pharmacology tailored to women's healthRationale for eliminating the hormone-free interval in modern oral contraceptivesMigraine in women: the role of hormones and their impact on vascular diseasesMenstrual suppression: current perspectivesTreatment of premenstrual dysphoric disorderExtended regimen combined oral contraception: A review of evolving concepts and acceptance by women and cliniciansUpdate on research and treatment of premenstrual dysphoric disorder.Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol for contraception and control of menstrual symptoms.Modulation of nociceptive threshold by combined hormonal contraceptives in women with oestrogen-withdrawal migraine attacks: a pilot studyOral contraceptives in migraine.Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest.Premenstrual syndrome and migraine.Extended and continuous combined contraceptive regimens for menstrual suppression.Treatment of heavy menstrual bleeding with the estradiol valerate and dienogest oral contraceptive pill.Hormone withdrawal-associated symptoms: overlooked and under-explored.Contraception and headache.Treatment of menstrual migraine: utility of control of related mood disturbances.Effect on carbohydrate metabolism and analysis of acceptability (menstrual cycle control) of extended regimens of the vaginally inserted hormone-releasing system 'NuvaRing' as compared with the standard 21/7 regime in reproductive-age women with typExtended-cycle oral contraceptive pills with 10 microg ethinyl estradiol pills in place of placebo pills.Ethinyl estradiol/drospirenone for the treatment of the emotional and physical symptoms of premenstrual dysphoric disorder.Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval.Efficacy and safety of an oral contraceptive containing ethinylestradiol 20 µg/drospirenone 3 mg (24/4 regimen) in three indications in the People's Republic of China: a comparison with international studies.Evaluation of hormonal suppression with two contraceptive regimens using ethinyl estradiol and desogestrel.The use of progestogen-only pill in migraine patients.There might be blood: a scoping review on women's responses to contraceptive-induced menstrual bleeding changes.
P2860
Q24650620-155A859B-5BA7-43E6-8D59-77ECD39ED4CAQ26745814-BD360837-75DF-42A6-A1AD-4694A760570CQ26749300-66FE8595-5C5D-4D09-8B68-55070E5760E9Q26853088-8C5446EC-4843-4BD0-938C-072E9C8E4AEDQ27026755-C6E7B21E-84DE-459B-A95A-49A0C8F6AA71Q28300895-D0B5C6C2-A05E-42F7-8803-5E2EA341820FQ28392784-034B3DD7-932F-4861-B439-13FC9F575366Q30475462-84E13CFB-4286-4F2E-B5A3-58390F3FBCADQ37059046-4ED31E52-1718-4B98-ACF7-AB86BEFBE825Q37150188-B6C7D129-F787-44BF-A78B-487E65188B52Q37409501-41D020FA-7576-4F89-AB16-ABFAB98EF043Q37724251-BE6E679D-21AE-4B5C-91D9-00D1BEB5A1A0Q38014293-4C7267A6-B93E-4A14-9410-1AC4FA439C98Q38065342-02C5BC0A-9694-4709-B69C-4A612974F51FQ38067360-DC5F5DE1-BDD5-45AF-BE42-C2FF59130955Q38082793-A52B5EE8-ADD4-407B-9FE9-E7ABA4A27BB3Q38083769-9A96AE9C-669C-4486-96D9-095A21DF0193Q38202138-77FED6FA-E059-416F-9FD1-6DE1B79E697EQ43119905-588F3A0E-920A-4B16-927B-314FC1E40025Q43267022-04B57323-4626-43A5-9D67-50DC0195082EQ43267026-4500FBE4-6820-48C4-85B0-02CE7BC22FE2Q46669787-F4950AAA-495F-48F7-B16B-5898D18587EFQ47549801-84E33732-D6C1-4F82-AE10-AFB00EE74974Q48377661-EA98C410-72D4-42AC-971C-F4F386D07A4DQ48907575-1864C930-AAD4-4681-B7E5-41E97B494E44Q55429258-353DCDF1-5B28-494A-B38F-959A184AEFB4
P2860
Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Acceptance of altering the sta ...... e hormone withdrawal symptoms.
@ast
Acceptance of altering the sta ...... e hormone withdrawal symptoms.
@en
Acceptance of altering the sta ...... e hormone withdrawal symptoms.
@nl
type
label
Acceptance of altering the sta ...... e hormone withdrawal symptoms.
@ast
Acceptance of altering the sta ...... e hormone withdrawal symptoms.
@en
Acceptance of altering the sta ...... e hormone withdrawal symptoms.
@nl
prefLabel
Acceptance of altering the sta ...... e hormone withdrawal symptoms.
@ast
Acceptance of altering the sta ...... e hormone withdrawal symptoms.
@en
Acceptance of altering the sta ...... e hormone withdrawal symptoms.
@nl
P2093
P356
P1476
Acceptance of altering the sta ...... e hormone withdrawal symptoms.
@en
P2093
Bobby L Shull
Mirian Ortiz
Patricia J Sulak
Thomas J Kuehl
P304
P356
10.1067/MOB.2002.122988
P407
P577
2002-06-01T00:00:00Z